TR
EN
Could Eosinopenia be a simple, fast and reliable biomarker in diagnosis of Covid-19?
Abstract
Objective: Monitoring CBC subsets, particularly eosinophils. and inflammation markers, during admission and treatment of severe COVID-19 patients, can reveal key indicators of disease progression and stage to provide a basis for diagnosis and treatment for clinicians.
Method: Our study is a retrospective case-control study. After taking aproval of Ministry of Health and Ethics Committee, the recorded clinical, laboratory and radiological data of 30 patients who were diagnosed with Covid-19, between 15 March and 15 June 2020, were compared with 30 healthy person by using appropriate statistical methods.
Results: Both patients and conrols included 10 (33.3%) females and 20 (66.6%) males with a mean age of 57.2 ± 15.46 and 60.07 ± 20.59 respectively. Eosinophil counts of the patients on admission were significantly lower than the controls (p <0.001). Eosinophil counts one week after admission were increased significantly compared to the admission levels (p= 0.004). Neutrophil/Eosinophil ratio, which is a reliable indicator of 'Eosinopenia' in patients on admission was significantly higher than that of one week later (p= 0.041). EO1, NE1, NE2, PLT2/LYM2, LYM1/CRP1 and LYM2/CRP2 were the most predictive indexes. The AUCs of them were; 0.856, 0.778, 0.719, 0.738, 0.747 and 0.702 respectively, the cut-off values were; 0.04, 3.32, 3.21, 144,59, 1.99 and 7.84 respectively, the sensitivity and specificity were 66.7% and 93.3% for EO1; 53.3% and 93.3% for NE1; 46.7% and 93.3% for NE2; and 80.1% and 80.5% for PLT2/LYM2; and 100% and 66.7% for LYM1/CRP1and 100% and 53.3% for LYM2/CRP2; respectively.
Conclusions: Tracking of CBC subsets, particularly Eosinophil, and CBC indexes is helpful in the early screening, diagnosis, treatment and follow up of critical COVID-19 patients.
Keywords
Kaynakça
- 1. Zhu N, Zhang D, Wang W. China Novel Coronavirus Investigating and Research Team. A novel coronavirus from patients with pneumonia in China, 2019 [published January 24, 2020]. N Engl J Med.
- 2. Jebril N. World Health Organization declared a pandemic public health menace: A systematic review of the coronavirus disease 2019 “COVID-19”, up to 26th March 2020. Available at SSRN 3566298. 2020.
- 3. Rothenberg ME, Hogan SP. The eosinophil. Annual review of immunology. 2006;24.
- 4. Weller PF, Spencer LA. Functions of tissue-resident eosinophils. Nature Reviews Immunology. 2017;17(12):746-60.
- 5. Busse W, Chupp G, Nagase H, Albers FC, Doyle S, Shen Q, et al. Anti–IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: Indirect treatment comparison. Journal of Allergy and Clinical Immunology. 2019;143(1):190-200. e20.
- 6. Rodriguez C, Veciana C. ASTHMA AND COVID-19: THE EOSINOPHILIC LINK. Qeios. 2020.
- 7. Akuthota P, Wang H, Spencer L, Weller P. Immunoregulatory roles of eosinophils: a new look at a familiar cell. Clinical & Experimental Allergy. 2008;38(8):1254-63.
- 8. Nagase H, Okugawa S, Ota Y, Yamaguchi M, Tomizawa H, Matsushima K, et al. Expression and function of Toll-like receptors in eosinophils: activation by Toll-like receptor 7 ligand. The Journal of Immunology. 2003;171(8):3977-82.
Ayrıntılar
Birincil Dil
İngilizce
Konular
Sağlık Kurumları Yönetimi
Bölüm
Araştırma Makalesi
Yayımlanma Tarihi
31 Aralık 2020
Gönderilme Tarihi
7 Kasım 2020
Kabul Tarihi
22 Aralık 2020
Yayımlandığı Sayı
Yıl 2020 Cilt: 42 Sayı: 4
AMA
1.Katar M, Demir O. Could Eosinopenia be a simple, fast and reliable biomarker in diagnosis of Covid-19? CMJ. 2020;42(4):422-433. doi:10.7197/cmj.822996